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The patient-made term ‘Long Covid’ is, we argue, a helpful and 
capacious term that is needed to address key medical, 
epidemiological and socio-political challenges posed by diverse 
symptoms persisting beyond four weeks after symptom onset 
suggestive of coronavirus disease 2019 (COVID-19). An international 
movement of patients (which includes all six authors) brought the 
persistence and heterogeneity of long-term symptoms to widespread 
visibility. The same grassroots movement introduced the term ‘Long 
Covid’ (and the cognate term ‘long-haulers’) to intervene in relation to 
widespread assumptions about disease severity and duration. 
Persistent symptoms following severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) infection are now one of the most pressing 
clinical and public health phenomena to address: their cause(s) is/are 
unknown, their effects can be debilitating, and the percentage of 
patients affected is unclear, though likely significant. The term ‘Long 
Covid’ is now used in scientific literature, the media, and in 
interactions with the WHO. Uncertainty regarding its value and 
meaning, however, remains. In this Open Letter, we explain the 
advantages of the term ‘Long Covid’ and bring clarity to some 
pressing issues of use and definition. We also point to the importance 
of centring patient experience and expertise in relation to ‘Long Covid’ 
research, as well as the provision of care and rehabilitation.
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Introduction
This Open Letter aims to contribute to multi-stakeholder 
discussions over how to conceptualize and respond to symp-
toms that persist several weeks after symptom onset suggestive 
of coronavirus disease 2019 (COVID-19). As authors, we all 
experience such symptoms and have contributed to interna-
tional patient advocacy in relation to the acknowledgement 
and conceptualization of such symptoms. We also bring inter-
disciplinary expertise from the humanities, interpretive social 
sciences, arts, medicine and public health, science policy, 
patient involvement, and ethics in research. The Open Letter 
explains why we believe that the patient-made term ‘Long 
Covid’ is a helpful and capacious term that is needed to address 
key medical, epidemiological and socio-political challenges 
posed by long-term symptoms. Persistent symptoms following 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
infection are now one of the most pressing clinical and pub-
lic health phenomena to address: their cause(s) is/are unknown, 
their effects can be debilitating, and the percentage of patients 
affected is unclear, though likely significant. The term ‘Long 
Covid’ has now been taken up in scientific literature, the 
media, and in clinical, policy, and governmental spaces. Uncer-
tainty regarding its value and meaning, however, remains. 
In this Open Letter, we explain the advantages of the term 
‘Long Covid’ and bring clarity to some pressing issues of use 
and definition.
What is ‘Long Covid’?
‘Long Covid’ is a patient-made term that, in the absence of 
formally agreed definitions, we use here to describe diverse 
symptoms persisting beyond four weeks after symptom onset 
suggestive of COVID-19. Many patients who have remained 
ill for months initiated support groups and grassroots cam-
paigns to bring the condition to visibility1–3. ‘Long Covid’ (and 
cognate ‘long-haul Covid’) now appears in journals4,5, and 
has been used by clinical and governmental actors and WHO 
meetings6–8. Doubts and imprecision about its meaning 
remain, however, and an epidemiological definition is needed. 
For this, two other definitions must be established: a clini-
cal case definition of COVID-19, which does not solely rely 
on laboratory confirmation; and a sophisticated definition for 
recovery that accounts for relapsing illness9,10. Once those 
definitions are in place, quantifying ‘Long Covid’ by exclud-
ing what it is not, ‘Long Covid’ remains a capacious and pow-
erful term – one that has passed from patients to use by the 
WHO in under three months.
‘Long Covid’ was first used by Perego11 as a contraction of 
long-term Covid illness to engage with her experience of 
a cyclical, multiphasic, and multi-system condition extend-
ing – temporally and clinically – beyond a biphasic pathway 
identified, for example, by Lescure et al.12. The cognate term 
‘long haulers’ was independently established by Watson for the 
support group she founded13, and brought to wide atten-
tion by Yong14. Exchanges amongst patients, as well as print 
and broadcast journalism, have been central in consolidat-
ing both terms. Patient-led surveys made visible the diversity 
and persistence of symptoms15; these findings are now being 
replicated in peer-reviewed journals16,17. Scientists do not yet 
know what causes long-term symptoms18 and incidence 
remains uncertain: case studies indicate 10–87% present per-
sistent symptoms or fail to return to their health baseline 
three weeks after onset16,17,19. These figures, however, derive 
from heterogeneous study designs and samples.
We argue here that ‘Long Covid’, as an open and malle-
able term, has many advantages for describing persist-
ent symptoms and/or sequelae of infection, as well as for 
navigating the dramatic scientific and socio-political chal-
lenges posed by the pandemic. In addition to itemizing these 
advantages below, we point to important considerations we 
believe should be kept in mind when conceptualizing and 
defining ‘Long Covid’.
Composite and multi-dimensional
‘Long Covid’ points to vastly variable clinical manifestations. 
It may incorporate several conditions with different aetiolo-
gies and more than one mechanism, even in the same patient. 
Effects in multiple organs have been documented20,21. On-
going fatigue appears common22–24. While waiting for further 
research, ‘Long Covid’ may, mechanistically, include patients 
with symptoms variously deriving from direct viral damage, 
immune response damage, opportunistic bacterial infections, and 
post-viral/post-sepsis symptoms25–27. Additional post-traumatic 
and mental health symptoms might interact with physiological 
symptoms in complex ways28,29. ‘Long Covid’ accounts for 
the possibility of persistent viral infection with low levels 
of viral shedding; protracted immune reaction; latency; or 
the presence of virus in reservoir organs or tissues27,30. 
SARS-CoV-2 also appears to be able to reinfect31, and to have 
the potential to precipitate new disease32–34.
‘Long Covid’ patients require prompt, multidimensional diag-
nostic investigations and treatment – not least to rule out poten-
tially life-threatening developments5. Those who were not 
hospitalized, and those who were not tested or have nega-
tive PCR/antibody tests, must be able to access diagnostic and 
therapeutic services5. Trauma and psychological symptoms are 
reported in both hospitalized and non-hospitalized survivors 
and need to be addressed sensitively28. Differential diagno-
sis that does not reduce ‘Long Covid’ to psychological symp-
toms is crucial. We urge researchers and clinicians to tread 
a careful line which: (i) does not assume that symptoms are 
caused by anxiety; (ii) acknowledges that COVID-19 is fre-
quently a traumatic experience; (iii) considers many potential 
mechanisms in explaining mental health symptoms – including 
inflammatory responses and neurological damage21,28,35.
Disease severity
‘Long Covid’ intervenes in early classifications of COVID-19 
as mild, severe, and critical, built on reports from Wuhan36,37. 
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COVID-19 was initially assumed to be a respiratory disease: 
classification was based around pneumonia severity and respiratory 
and/or multiple organ failure. It has become clear this 
categorisation does not do justice to heterogeneous disease 
trajectories. COVID-19is now primarily characterized as a multi-
systemic disease: mild manifestations in the prodromal stage can 
progress to severe disease12 and sequelae, including cardiovascu-
lar, thrombotic, and neurological manifestations26,38. Interstitial 
COVID-19 pneumonia can be asymptomatic/pauci-symptomatic, 
challenging any easy adjudication of severity39. Heterogeneous 
disease pathways and comorbidities – particularly those render-
ing people vulnerable, e.g. dementias – are likely to make it harder 
to parse ‘Long Covid’ symptoms. Aberrant immune response 
might be involved in persistent symptoms and additional organ 
damage27. By deconstructing the current mild vs severe 
dichotomy, ‘Long Covid’ underlines that hospitalization is 
an imperfect indicator of severity, even if has been used as 
such in studies. Criteria for admission varied from coun-
try to country, and within countries, and there are indications 
from hotspots that severely ill patients were not hospitalized40,41. 
To rely on hospitalization as a demarcation of severity creates 
skewed samples9, including poor representation of younger/ 
paediatric patients42,43. In any case, persistent symptoms impair-
ing an individual’s usual function and quality of life should 
not be called ‘mild’9,37.
Other clinical arenas indicate the difficulty of assessing whether 
severity criteria should be based on risk of death, symp-
tomatology, extent of impairment, or symptoms longevity44. 
‘Long Covid’ insists that definitional resolutions need to 
include the perspective and published records of multiple 
patients with different temporal and clinical pathways. This 
has significant implications both for the way that individu-
als are medically treated and cared for, and how risk of 
infection is approached at a population level.
Nature and duration of disease
While we provisionally define ‘Long Covid’ patients as those who 
have not recovered within four weeks from symptom onset, the 
point at which COVID-19 moves out of its acute phase remains 
unclear, and may vary in different patients12,26,45. Duration and final 
outcomes of, and recovery from, ‘Long Covid’ are also unclear. 
Further research needs to address the complex host-pathogen 
interaction46. While similarities between some ‘Long Covid’ symp-
toms and symptoms from conditions such as Myalgic encephalo-
myelitis/chronic fatigue syndrome (ME/CFS) and dysautonomia 
need to be investigated47,48, there is a risk of prematurely fram-
ing studies of ‘Long Covid’ through other diseases. This might 
downplay emerging phenomena specifically linked to COVID-19 
– such as the range of SARS-CoV-2 action via ACE2 recep-
tors widespread in the body, and the temporally and spa-
tially complex immune response to the virus – thereby 
missing thresholds for early intervention25,45.
‘Long Covid’, through assuming agnosticism in relation to 
an as yet not understood disease course, side-steps the prob-
lems of ‘post- ’ (e.g. ‘post-Covid syndrome’, ‘post-acute’) and 
‘chronic’. It advocates instead for a nuanced and personal-
ized approach to each patient – including monitoring and 
intervention both early in the infection and as a follow-up5,45.
Prevention and morbidity
We need to adequately assess both morbidity and mortality in 
‘Long Covid’ cohorts – including in those who were not tested 
at the time of infection or via effective serology screening, 
since testing is not exempt from pitfalls30. The personal, eco-
nomic and social costs of ‘Long Covid’ are unfathomable. They 
include screening; medical, rehabilitative and social care; and 
meeting costs associated with long-term disability, including 
lost productivity49. Research indicating sequelae, even in 
asymptomatic/pauci-symptomatic cases, suggests screening and 
treatment may be needed for millions. The impact on already 
marginalised/minoritised communities will be particularly pro-
found. ‘Long Covid’ calls for greater specificity in measuring 
‘symptom duration, fluctuation, overall functionality and qual-
ity of life in comparison to before infection’50. Understand-
ing ‘Long Covid’ is also crucial for prevention, and will help 
determine pandemic control policies.
Centring patients
‘Long Covid’ was made by grassroots, international move-
ments of people experiencing a new disease. Patients, many of 
them undergoing traumatic experiences in dramatic circum-
stances, engaged in self-reflection and observation, collective 
support, advocacy and activism. Many are closely involved 
in and engaging with fast-moving scientific literature; some 
are themselves clinicians and/or researchers9,37,50–52.
Patients should be involved in the commissioning of research 
and clinical services. Many bring relevant expertise and some 
convene/own patient-led archives hosting extensive clinical data.
‘Long Covid’ demands that medical professionals, the media 
and the wider community are sensitive to the trauma experi-
enced by patients53. Some were left untended, to die at home; 
many were misunderstood or had their symptoms reduced 
to anxiety54. Some have been caring for ill – or dying – fam-
ily and friends, and many have lost jobs or are under threat of 
losing their livelihoods, medical insurance or visa status. 
Patients’ datasets of symptoms, and potential therapeutics, carry 
risks of exploitation. Rapid gathering of DNA and other data 
from ‘Long Covid’ groups poses significant ethical challenges, 
including the use of sensitive information shared on different 
media to raise awareness in an unprecedented crisis.
Disability-inclusive
‘Long Covid’ is explicitly disability-inclusive. Many who made 
‘Long Covid’ – including some of us authors – have experi-
enced disability, suffered discriminatory healthcare practices, 
and draw on models developed within disability activism/
research55,56. ‘Long Covid’ also acknowledges the experiences 
of those who were healthy, or did not identify themselves 
as disabled/chronically ill, before infection. ‘Long Covid’ 
insists that long-term symptoms, disability, and rehabilitation 
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are complex phenomena extending beyond questions of biol-
ogy and physiology. They are entrenched unevenly within 
the socio-environmental milieu of communities57–60.
The perils of pandemic medicine
‘Long Covid’, with its aetiological openness, recognizes the 
risks inherent to emergency medicine. These include: specu-
lative therapies; inadequate care risking persistent/permanent 
damage; over-hasty diagnosis and diagnostic lumping – par-
ticularly in the context of trauma in clinicians and patients; lack 
of access to testing and diagnostic tools; and stigma. When 
in-depth testing evaluating biological markers is not available, 
or when such tests do not explain symptoms or the exact 
duration of viral persistence, the risk of misdiagnosis remains 
high.
‘Long Covid’ acknowledges the potential for persistent ill-
ness to be caught up in political and medical misunder-
standings and exploitation. The definition and treatment of 
complex phenomena (‘Long Covid’) that emerge in relation 
to an equally complex, currently not well understood disease 
(COVID-19), itself of contingent definition, are full of danger. 
We do not currently know whether all ‘Long Covid’ patients 
are indeed ‘post-viral’.
Anthony Fauci has stated that a COVID-19 ‘post-viral 
syndrome’ is ‘strikingly similar to myalgic encephalomyeli-
tis/chronic fatigue syndrome’61. While we acknowledge the 
importance of investigating comparisons with other diagnos-
tic entities, we argue however against enfolding ‘Long Covid’ 
within other diagnoses. We need a label distinct from other 
phenomena related to earlier viral and other exposures (e.g. ME/
CFS). We also question the term ‘Post-Covid Syndrome’: we 
believe it carries not only risks of misdiagnoses and mismanage-
ment, but also of leaving those with persistent illness behind, 
especially in a post-vaccine world.
Conclusion
The term ‘Long Covid’ emphasizes the only aspect of illness 
comprising persistent symptoms about which there is currently 
certainty: illness is long in relation to the prevalent early public 
message of two weeks of illness in mild COVID-19 cases36,62. The 
simplicity and strength of ‘Long Covid’ as a term helps the fight 
for fair recognition on a global scale, and calls for care, equity, 
compassion, and collective action – involving prominent 
actors, stakeholders, and activists. It is founded on demands 
for a nuanced, patient-focused approach – one incorporating 
wide-ranging investigations of potential post-viral conditions 
but, crucially, recognizing the pathogenesis of SARS-CoV-
2 as specific in its own right. We need to avoid the severity or 
prevalence of ‘Long Covid’ being downplayed – whether for 
political purposes, privileging the claims that the economy is 
at odds with reducing levels of infection, or for fear of inad-
equately resourced healthcare systems37. We need to ensure 
the public knows about the potential ‘Long Covid’ conse-
quences of infection when they are balancing the risks of 
exposure to SARS-CoV-2.
In coming months, it is possible some clinical sub-disciplines 
or research groups, might be favoured – especially if specific 
medical/legal definitions for those with long-term symp-
toms are imposed or achieved. Which patients might be left 
out? How will funds be allocated for research and treat-
ment? Who will qualify for disability benefits/sick pay? How 
can we ensure that evidence about variation in patients is not 
disregarded and exacerbates inequalities?
‘Long Covid’ calls for collective responses to such questions, 
in which the expertise of ‘Long Covid’ patients is recog-
nised within multi-disciplinary teams of researchers, stake-
holders and care providers. Extensive involvement of ‘Long 
Covid’ patients has the best chance of ensuring that concep-
tualization, investigation and treatment of ‘Long Covid’ are 
attentive to the cultures, health systems, and discriminatory 
societies where patients live35,60. ‘Long Covid’ must not be 
understood as the outcome of biological processes alone.
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